Evidence map›Paper›PMID 36588796›Full record

ArticleAnalytical cellular pathology (Amsterdam)2022

CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.

Kai Li, Tingting Fan, Zhongxing Shi, Huijie Jiang

Open access · goldAbstract read
In one paragraph

Article in Analytical cellular pathology (Amsterdam), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Cancers · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kai LiDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Tingting FanDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Zhongxing ShiDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Huijie JiangDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.ORCID https://orcid.org/0000-0001-7321-5297
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is a highly aggressive and solid malignancy with a poor prognosis. Cell division cycle associated 2 (CDCA2) is highly expressed in HCC and is considered to be closely related to the prognosis of patients with HCC. In this research, we aimed to investigate the function and potential mechanism of CDCA2 in HCC cells. Methods: Gain- and loss-of-function experiments were conducted to determine the biological function of CDCA2 in HCC cells. Quantitative reverse transcription-polymerase chain reaction and western blot were utilized to examine the Messenger RNA (mRNA) and protein levels of CDCA2 in HCC cells. The malignant behaviors of HCC cells were analyzed by several biological experiments including cell viability, cell colony formation, and transwell assays. Western blot was also implemented to examine the expression of : AKT, protein kinase B and mTOR, mammalian target of rapamycin (AKT-mTOR) pathway related proteins and Cyclin D1. Results: A significant increase of CDCA2 was observed in HCC cell lines. Upregulation of CDCA2 resulted in the enhancement of the growth, migration, and invasion of HCC cells. Inversely, depletion of CDCA2 displayed the opposite results. Furthermore, the protein levels of p-AKT, p-mTOR, and Cyclin D1 were elevated with CDCA2 upregulation and reduced with CDCA2 depletion in HCC cells. Conclusion: Our observations revealed that CDCA2 promoted the malignant development of HCC cells, and AKT-mTOR pathway might involve in the underlying mechanism.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCarrier ProteinsCell Cycle ProteinsCell Line, TumorCell MovementCell ProliferationCyclin D1Gene Expression Regulation, NeoplasticHumansNuclear ProteinsProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesCarrier ProteinsCDCA2 protein, humanCell Cycle ProteinsCyclin D1MTOR protein, humanNuclear ProteinsProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Identifiers

PMID36588796
PMCPMC9800082
OpenAlexW4312190731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.